Additionally, we found that PD-1 mRNA levels in CRC tumor tissue and circulation were higher in early stages, suggesting that targeting PD-1 in CRC patients with advanced stages could be less effective. The gene discussed is PDCD1; the disease is colorectal carcinoma.